ACRS
Aclaris Therapeutics Inc
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 108.94M; Volume: 73.34K; AvgVol 3m: 569.78K; Beta: 1.29;
Cost estimate:
P/E: –; EPS: -1.67; EPS growth quarter/prev quarter: 74.10%;
EPS growth this year: -10.10%; EPS growth past 5 years: -57.10%;
EPS ttm: -1.67;
P/S: 23.08; P/B: 2.84; P/Cashflow: 1.86; P/FCF: ;
Sales: 5.53M; Sales growth quarter/prev quarter: 122.20%; Sales growth past 5 years: ;
Profitability:
Gross Margin: 18.40%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -91.80%; ROE – return on equity: -153.90%; LT Debt/Equity: 0.21; Total Debt/Equity: 0.23;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 3.90%; Insider Transactions:0.00%;
Institutional Ownership: 71.00%; Institutional Transactions: -13.87%;
Data update: 07.10.2020.